Severe COVID-19: Immunosuppression or Hyperinflammation?

被引:21
|
作者
Liu, Ye [1 ,2 ]
Li, Yiming [1 ,2 ]
Xu, Dongxue [1 ,2 ]
Zhang, Jing [1 ,2 ]
Peng, Zhiyong [1 ,2 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, Donghu Rd 169, Wuhan 430071, Hubei, Peoples R China
[2] Clin Res Ctr Hubei Crit Care Med, Wuhan, Hubei, Peoples R China
来源
SHOCK | 2021年 / 56卷 / 02期
基金
中国国家自然科学基金;
关键词
COVID-19; hyperinflammation; immunosuppression; immunotherapy; SARS-CoV-2; ANTIBODY-DEPENDENT ENHANCEMENT; CONVALESCENT PLASMA THERAPY; ALPHA-INDUCED APOPTOSIS; SUPPRESSOR-CELLS; TNF-ALPHA; INTRAVENOUS IMMUNOGLOBULIN; CORTICOSTEROID-THERAPY; ENDOTHELIAL-CELLS; SARS CORONAVIRUS; STROMAL CELLS;
D O I
10.1097/SHK.0000000000001724
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The ongoing coronavirus disease 2019 (COVID-19) pandemic has swept over the world and causes thousands of deaths. Although the clinical features of COVID-19 become much clearer than before, there are still further problems with the pathophysiological process and treatments of severe patients. One primary problem is with the paradoxical immune states in severe patients with COVID-19. Studies indicate that Severe Acute Respiratory Syndrome Coronavirus 2 can attack the immune system, manifested as a state of immunosuppression with a decrease in lymphocytes, whereas a state of hyperinflammation, presenting as elevated cytokine levels, is also detected in COVID-19. Therefore, discussing the specific status of immunity in COVID-19 will contribute to the understanding of its pathophysiology and the search for appropriate treatments. Here, we review all the available literature concerning the different immune states in COVID-19 and the underlying pathophysiological mechanisms. In addition, the association between immune states and the development and severity of disease as well as the impact on the selection of immunotherapy strategies are discussed in our review.
引用
收藏
页码:188 / 199
页数:12
相关论文
共 50 条
  • [1] Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
    Ritchie, Andrew I.
    Singanayagam, Aran
    LANCET, 2020, 395 (10230): : 1111 - 1111
  • [2] Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
    Papadopoulou, Charalampia
    Al Obaidi, Muthana
    Moraitis, Elena
    Compeyrot-Lacassagne, Sandrine
    Eleftheriou, Despina
    Brogan, Paul
    RHEUMATOLOGY, 2021, 60 (02) : 911 - 917
  • [3] Immunopathology of Hyperinflammation in COVID-19
    Gustine, Joshua N.
    Jones, Dennis
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (01): : 4 - 17
  • [4] Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study
    Liu, Heng
    Zhou, Liang
    Wang, Hugen
    Wang, Xiaobo
    Qu, Guangbo
    Cai, Jing
    Zhang, Hong
    NUTRITION IN CLINICAL PRACTICE, 2021, 36 (04) : 863 - 871
  • [5] Management of hyperinflammation in COVID-19 patients
    Suberviola, Borja
    Cuenca Fito, Elena
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 6 - 9
  • [6] Hyperinflammation as underlying mechanism predisposing patients with cardiovascular diseases for severe COVID-19
    Landmesser, Ulf
    Lehmann, Irina
    Eils, Roland
    EUROPEAN HEART JOURNAL, 2021, 42 (18) : 1720 - 1721
  • [7] Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19
    Zaid, Younes
    Dore, Etienne
    Dubuc, Isabelle
    Archambault, Anne-Sophie
    Flamand, Olivier
    Laviolette, Michel
    Flamand, Nicolas
    Boilard, Eric
    Flamand, Louis
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (02) : 368 - +
  • [8] Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19
    Zhao, Xinyi
    Zhou, Lijin
    Kou, Yan
    Kou, Junjie
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (03): : 1454 - 1468
  • [9] Attenuating hyperinflammation in COVID-19: A change in paradigm?
    Molnar, Zsolt
    Bakker, Jan
    JOURNAL OF CRITICAL CARE, 2020, 60 : 334 - 336
  • [10] IgGs drive COVID-19 myeloid hyperinflammation
    Park M.D.
    Nature Reviews Immunology, 2020, 20 (9) : 521 - 521